Darnell, Anna
Rimola, Jordi
Belmonte, Ernest
Ripoll, Enric
Garcia-Criado, Ángeles
Caparroz, Carla
Díaz-González, Álvaro
Vilana, Ramón
Reig, María
Ayuso, Carmen
Bruix, Jordi
Forner, Alejandro
Funding for this research was provided by:
ISCIII (PI18/00542)
Article History
Received: 5 May 2020
Revised: 15 September 2020
Accepted: 3 November 2020
First Online: 6 January 2021
Compliance with ethical standards
:
: The scientific guarantor of this publication is Alejandro Forner.
: The authors of this manuscript declare relationships with the following companies:Anna Darnell, Álvaro Díaz-González, and Carmen Ayuso: Speaker fees and travel grants from Bayer.Jordi Rimola: Speaker fees and travel grants from Bayer. Consultancy fees COR2ED.Ernest Belmonte: Travel grants from BTG.Enric Ripoll, Carla Caparroz, and Ramón Vilana: None.Ángeles García-Criado: Speaker fees from BTG and Terumo.María Reig: Consultancy from Bayer, BMS, Roche, Ipsen, AstraZeneca, and Lilly. Lecture fees from Bayer, BTG, BMS, Gilead, and Lilly. Research grants from Bayer and Lilly.Jordi Bruix: Consultancy from Arqule, Bayer, Novartis, BMS, BTG-Biocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance, Roche, AbbVie, Merck, Sirtex, Ipsen, Astra-Medimmune, Incyte, Quirem, Adaptimmune, and Lilly. Research grants from Bayer and BTG. Educational grants from Bayer and BTG. Lecture fees from Bayer, BTG-Biocompatibles, Eisai, Terumo, Sirtex, and Ipsen.Alejandro Forner: Speaker fees from Bayer, Gilead, and MSD; consultancy fees from Bayer, AstraZeneca, and Guerbert.None of those declared company relationships are related to the subject matter of the article.
: No complex statistical methods were necessary for this paper. Noteworthy, the corresponding author of this article (Alejandro Forner) has a degree on Investigation Methodology in Health Science and a Master in Methodology of Investigation in Health Science by the Universidad Autónoma de Barcelona, Spain.
: Written informed consent was waived by the institutional review board.
: Institutional review board approval was obtained.
: Part of the population study was previously reported to validate the non-invasive diagnostic criteria for hepatocellular carcinoma (Forner A et al <i>Hepatology</i> 2008; 47:97–104), the limited value of intratumoral fat or peritumoral capsule to increase the diagnostic accuracy of MRI (Rimola J et al <i>Journal of Hepatology</i> 2012;56:1317–1323), and the evaluation of the diagnostic accuracy of LI-RADS v2013 (Darnell A et al <i>Radiology</i>. 2015;275:698–707). However, the results of the present study and the previous do not overlap and do not contain redundant information. In particular, the latter study in 2015 by Darnell et al included 133 patients and the lesions were evaluated according to LI-RADS v2013. In the present study, we included 129 additional patients, and the LI-RADS assessment was done with v2018.
: • Retrospective analysis of a prospective protocol• Diagnostic or prognostic study• Performed at one institution